Pharmacyclics Inc

Pharmacyclics — 12th International Conference on Malignant Lymphoma (ICML), Lugano 2013

20 slides from Pharmacyclics's conference presentation, Jun 19, 2013

  1. Slide 1: Single agent ibrutinib (PCI-32765) is highly effective in CLL patients with 17p deletion

    Slide 1: Single agent ibrutinib (PCI-32765) is highly effective in CLL patients with 17p deletion

    Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia (CLL) patients with 17p deletion Adrian Wiestner, MD/PhD Hematology Branch, NHLBI, National Institutes of Health Bethesda, MD ds Ns», & \ National Heart sy %, Lung and Blood Institute E@®: oo People Science Health

  2. Slide 2: Disclosures: Adrian Wiestner

    Slide 2: Disclosures: Adrian Wiestner

    Disclosures: Adrian Wiestner + Employee of the National Heart, Lung, and Blood Institute. + Supported by the Intramural Research Program, NHLBI, NIH. + Ibrutinib is an investigational agent that is currently not approved and is provided by Pharmacyclics. National Heart Lung and Blood Institute Peopl

  3. Slide 3: Chronic lymphocytic leukemia

    Slide 3: Chronic lymphocytic leukemia

    Chronic lymphocytic leukemia Accumulation of mature clonal B-cells in CLL: >5,000 clonal B-lymphocytes/uL of blood, CD19+, CD5+, CD23+, CD20 dim, FMC7 negative Small Lymphocytic Lymphoma (SLL): same biology, <5,000 clonal B-lymphocytes / uL of blood A. Wiestner, 12" ICML, Lugano June 19-22, 2013

  4. Slide 4: Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab

    Slide 4: Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab

    Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab es mare 2 Less effective % for CLL with 6 deletion of 17p Survival so (del 17p). (%) x Less tolerable ao} — 4 in elderly / frail f= patients. — Not 17p-/119-/+12q/13¢- i 0 6 bo my BO GO “Time since randomisation (mont

  5. Slide 5: B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL

    Slide 5: B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL

    B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL Antigen scr _@, o \Z a cp79 extracellular 1 [PIP2 | PIP3 intracellular s s PSK, Ee v Y BTK p» =mTOR WN Kp LYN K ‘ Proliferation, ===> survival, Migration A.. Wiestner, 12” ICML, Lugano June 19-22, 2013 Modified from Wiestner, CO 2013

  6. Slide 6: BCR signaling is ongoing in CLL and is primarily active in the lymph node

    Slide 6: BCR signaling is ongoing in CLL and is primarily active in the lymph node

    BCR signaling is ongoing in CLL and is primarily active in the lymph node Activation of SYK kinase downstream of the BCR Blood Lymph node cs 25% | 14.6% ye fo vl a ° Te Te we ee ‘A. Westner, 12" ICML, Lugano June 19-22, 2013 Upregulation of BCR target genes Blood Bone Lymph marrow node genes Herisha

  7. Slide 7: Ibrutinib, a covalent inhibitor of BTK, disrupts BCR signaling

    Slide 7: Ibrutinib, a covalent inhibitor of BTK, disrupts BCR signaling

    Ibrutinib, a covalent inhibitor of BTK, disrupts BCR signaling extracellular intracellular Ibrutinib (PCI-32765) . Cienoute to ont Modified from Wiestner, JCO 2013. 7

  8. Slide 8: Study design

    Slide 8: Study design

    Study design (12-H-0035, Hematology, NHLBI) Off Treatment: Progressive pe Disease (28 day cycles) CLL/SLL 17p deletion or p53 Response Continue mutation at 6 Treatment 420 months mg daily 5 6 Screen 1 2 3 4 relapsed and treatment \ i | naive Blood and lymph node for correlative Off Treatment: Intole

  9. Slide 9: Study population 17p deletion

    Slide 9: Study population 17p deletion

    Study population 17p deletion Del 17p, n = 29, * 15 (52%) treatment * Age 33-83 year naive (TN) - evaluable . 9 13 (1 death, 1 pre- ners male existing HD) * 66% Rai stage 23 52% bulky disease + 14 (48% (48%) (longest diameter >5cm) relapsed/refractory (R/R) — evaluable 13 (1 death) * 62% splenomegal

  10. Slide 10: Safety and tolerability

    Slide 10: Safety and tolerability

    Safety and tolerability + Most common adverse events (grade 1-2): diarrhea, rash, arthralgia, cramps, mouth sores, fatigue. * Grade 23 non-hematologic AEs (13% of patients): infection, rash. + Hematologic adverse events rare. + No drug discontinuation for adverse events. + Dose reductions for recurr

  11. Slide 11: Pre-treatment At months on ibrutinib

    Slide 11: Pre-treatment At months on ibrutinib

    Pre-treatment At 2 months on ibrutinib

  12. Slide 12: Response to ibrutinib at months

    Slide 12: Response to ibrutinib at months

    Response to ibrutinib at 6 months 17p deletion (n=26) % decrease in adenopathy PR (IWCLL) ™ PR with lymphocytosis =PD Ab A.. Wiestner, 12" ICML, Wagener 1822, 2018 12-H-0035, Hematology, NHLBI 12

  13. Slide 13: Volumetric measurement of spleen response at months

    Slide 13: Volumetric measurement of spleen response at months

    Volumetric measurement of spleen response at 6 months % decrease in spleen volume | 25 | -50 75 A.. Wiestner, 12" ICML, Lugano June 19-22, 2013 12-H-0035, Hematology, NHLBI 13

  14. Slide 14: Bone marrow response at months

    Slide 14: Bone marrow response at months

    Bone marrow response at 6 months CcD79a Pre-treatment At6 months Men A.. Wiestner, 12 ICML, Lugano June 19-22, 2013 % change in tumor burden 50 100 12-H-0035, Hematology, NHLBI 14

  15. Slide 15: Transient lymphocytosis, followed by disease resolution in CLL patients on ibrutinib

    Slide 15: Transient lymphocytosis, followed by disease resolution in CLL patients on ibrutinib

    Transient lymphocytosis, followed by disease resolution in CLL patients on ibrutinib % change in ALC % change at 6 months 150 100 I Txnaive 400 Relapsed refractory 50 Mean (#/-sem) 50 % of pre- 0 - aera treatment I ALC -50 Mili -50 > Txnaive ~& Relapsed / refractor -100 si "y 400 0 60 120 180 A. Wes

  16. Slide 16: Effect of ibrutinib on subclonal composition

    Slide 16: Effect of ibrutinib on subclonal composition

    Effect of ibrutinib on subclonal composition Patient with relapsed CLL % change in 17p clone size after 6 months on drug non 80 Baseline 17p = **& >90% decrease in CLL count: CLL cell count 84K/uL 6 months CLL count: non 7K/uL 17p CLL with baseline >25% del 17p 80 + A.. Wiestner, 12" ICML, Lugano du

  17. Slide 17: Responses to ibrutinib appear durable in both populations

    Slide 17: Responses to ibrutinib appear durable in both populations

    Responses to ibrutinib appear durable in both populations _ =a PFS probability «| “| PFS estimate at 15 months: — treatment naive (n=14): 87% “| — relapsed/refractory (n=14): 85% Months on Study . AsMMesiner, 127 OME, 12-H-0035, Hematology, NHLBI 17 Lugano June 19-22, 2013

  18. Slide 18: Ibrutinib inhibits tumor proliferation and BCR signaling in the lymph node

    Slide 18: Ibrutinib inhibits tumor proliferation and BCR signaling in the lymph node

    Ibrutinib inhibits tumor proliferation and BCR signaling in the lymph node BCR signaling activity Gene expression day 2/ baseline 2 (log2) at—_——_. Day2 A.. Wiestner, 12" ICML, cer ee 12-H-0035, Hematology, NHLBI 18

  19. Slide 19: Summary and conclusions

    Slide 19: Summary and conclusions

    Summary and conclusions * Ibrutinib as a single agent is well tolerated and highly effective in CLL with 17p deletion: — Excellent responses in treatment naive and relapsed refractory patients. — Responses appear durable. * Substantial disease reduction in all anatomic sites: — complete response in

  20. Slide 20: Supported by the Intramural Research Program of NHLBI/NIH

    Slide 20: Supported by the Intramural Research Program of NHLBI/NIH

    Supported by the Intramural Research Program of NHLBI/NIH Irina Maric Laboratory Medicine Stefania Pittaluga Diane Arthur Pathology Richard Cheng Francine Thomas Radiology Xin Tian Office of Biostatistics Research Our patients for partici Mohammed Farooqui Sarah Herman Georg Aue Rashida Mustafa Nakh

Source: SEC EDGAR · 8-K filed Jun 19, 2013

More decks from Pharmacyclics Inc